BioSpace News Archive

Boehringer Ingelheim leverages CelerisTx’s proprietary AI-based platform to generate novel proximity-inducing compounds to degrade pathogenic proteins

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today, in partnership with Foresee Pharmaceuticals Co., Ltd., the U.S. launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

Sudden cardiac arrest (SCA), as the name suggests, can happen any time and to anyone regardless of age and location. Every second, minute counts when a person collapses in SCA.

Surge in prevalence of animal diseases led to the need of development of animal vaccines. Governments and market players have been taking various efforts to speed up development of vaccines that target different conditions among animals.

Bright Peak Therapeutics today announced the acceptance of one oral presentation and two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022, in New Orleans, Louisiana.

Corcept Therapeutics Incorporated today announced completion of enrollment in GRATITUDE – the company’s double-blind, placebo-controlled trial of its proprietary, selective cortisol modulator miricorilant as a potential treatment for patients with weight gain caused by antipsychotic medication use.

Kala Pharmaceuticals, Inc. today announced that it will present data from a previously completed Phase 1b clinical trial of KPI-012 in a poster session at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, Colorado, May 1-4, 2022 and virtually, May 11-12, 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that management will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022.

4D Molecular Therapeutics, Inc. announced that the first patient has been dosed in its Phase 1/2 clinical trial of 4D-710 in patients with cystic fibrosis.